Showing 231-240 of 273 results for "".
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- Practical Dermatology® Magazine Names Neal Bhatia, MD, FAAD Co-Chief Medical Editorhttps://practicaldermatology.com/news/20140117-practical_dermatology_magazine_names_neal_bhatia_md_faad_co-chief_medical_editor/2459367/Neal Bhatia, MD, FAAD, San Diego-based dermatologist and well known lecturer and author, has been named Co-Chief Medical Editor of Practical Dermatology® magazine from Bryn Mawr Communications III, LLC. Now in it's 11th year of publicat
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,